Literature DB >> 11827643

Rapid Eye Movement Sleep-related Parasomnias.

Matthias K. Lee1, Christian Guilleminault.   

Abstract

Among the rapid eye movement (REM) sleep-related parasomnias, the most common and important disorder for which patients present is REM sleep behavior disorder (RBD). Rapid eye movement sleep behavior disorder is often undiagnosed for many years, despite the sometimes bizarre and harmful behaviors involved. Complete evaluation and accurate diagnosis are essential for proper management. This includes medical, sleep/wake, psychiatric, and neurologic histories. Although they may raise feelings of guilt or shame, questions related to sexual and violent behaviors should be directed towards the identified patient as well as their bed partners. Objective studies should include nocturnal polysomnogram with audiovisual monitoring of behavior, electromyography (EMG) of all limbs, and seizure montage. Brain imaging, clinical electroencephalogram (EEG), neuropsychometric testing, and actigraphy may be used adjunctively. Clinicians should have a high index of suspicion for other neurologic conditions, especially neurodegenerative disorders and narcolepsy, because many patients with RBD have these conditions. Rapid eye movement sleep behavior disorder may actually precede symptoms and signs associated with other neurologic disorders, so close follow-up is recommended. Medications that may be causing or exacerbating RBD should be withdrawn, if possible. Clonazepam is very effective in reducing the symptoms of RBD. This treatment is generally well tolerated and may be used long-term. Discontinuation of clonazepam usually leads to relapse of symptoms. Safety-related issues should be discussed with patients and their families.

Entities:  

Year:  2002        PMID: 11827643     DOI: 10.1007/s11940-002-0019-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  10 in total

1.  The pathology of REM sleep behavior disorder with comorbid Lewy body dementia.

Authors:  R S Turner; C J D'Amato; R D Chervin; M Blaivas
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

2.  Decreased striatal dopaminergic innervation in REM sleep behavior disorder.

Authors:  R L Albin; R A Koeppe; R D Chervin; F B Consens; K Wernette; K A Frey; M S Aldrich
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

3.  Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases.

Authors:  E J Olson; B F Boeve; M H Silber
Journal:  Brain       Date:  2000-02       Impact factor: 13.501

4.  REM sleep behavior disorders in multiple system atrophy.

Authors:  G Plazzi; R Corsini; F Provini; G Pierangeli; P Martinelli; P Montagna; E Lugaresi; P Cortelli
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

5.  Violent behavior during sleep.

Authors:  M M Ohayon; M Caulet; R G Priest
Journal:  J Clin Psychiatry       Date:  1997-08       Impact factor: 4.384

6.  Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease.

Authors:  C L Comella; T M Nardine; N J Diederich; G T Stebbins
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

7.  Incidental Lewy body disease in a patient with REM sleep behavior disorder.

Authors:  M Uchiyama; K Isse; K Tanaka; N Yokota; M Hamamoto; S Aida; Y Ito; M Yoshimura; M Okawa
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

8.  Chronic behavioral disorders of human REM sleep: a new category of parasomnia.

Authors:  C H Schenck; S R Bundlie; M G Ettinger; M W Mahowald
Journal:  Sleep       Date:  1986-06       Impact factor: 5.849

9.  Olivopontocerebellar degeneration, abnormal sleep, and REM sleep without atonia.

Authors:  M A Salva; C Guilleminault
Journal:  Neurology       Date:  1986-04       Impact factor: 9.910

10.  Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

Authors:  C H Schenck; S R Bundlie; M W Mahowald
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.